Despite significant advances in early diagnosis and targeted therapy, the prognosis for lung cancer remains poor, with a five-year survival rate of less than 17% [12].Smoking, carcinoembryonic antigen (CEA) levels, histological features, molecular markers, and developed staging methods are used to evaluate the prognosis [2]. This evidence concerns the gene CEACAM5 and lung cancer.